Cargando…
Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
Autores principales: | Kow, Chia Siang, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097392/ https://www.ncbi.nlm.nih.gov/pubmed/33965134 http://dx.doi.org/10.1016/j.chest.2020.11.073 |
Ejemplares similares
-
Role of frailty in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020) -
The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
por: Kow, Chia Siang, et al.
Publicado: (2021)